liver cancer

BeiGene and Novartis Make Late-Stage Progress against Liver Cancer
BioSpace
Tue, 08/9/22 - 12:14 pm
Novartis
BeiGene
hepatocellular carcinoma
liver cancer
clinical trials
Merck's Keytruda, on a losing streak, fails in once FDA-rejected liver cancer use and prostate cancer—again
Fierce Pharma
Wed, 08/3/22 - 09:15 pm
Merck
Keytruda
FDA
liver cancer
Lenvima
Here's What AstraZeneca's Recent FDA News Means for Shareholders
Motley Fool
Mon, 05/30/22 - 10:15 am
AstraZeneca
FDA
Imfinzi
tremelimumab
liver cancer
After 18 years in development, AstraZeneca’s CTLA-4 antibody gets the red carpet treatment at the FDA
Endpoints
Mon, 04/25/22 - 10:20 am
AstraZeneca
FDA
tremelimumab
liver cancer
priority review
Exelixis throws in the towel on early-stage liver cancer after final readout shows OS flop
Endpoints
Tue, 03/15/22 - 10:39 am
Exelixis
Cabometyx
liver cancer
clinical trials
ASCO-GI – immuno-oncology makes progress in liver cancer
EP Vantage
Fri, 01/21/22 - 10:37 am
AstraZeneca
Imfinizi
tremelimumab
ASCO-GI
liver cancer
Almost three years after whiffing in a confirmatory study, Merck touts new data for Keytruda in HCC
Endpoints
Wed, 01/19/22 - 10:59 am
Merck
Keytruda
liver cancer
HCC
AstraZeneca: Imfinzi Plus Tremelimumab Improves OS In Phase III Trial In Liver Cancer
NASDAQ
Fri, 10/15/21 - 11:03 am
AstraZeneca
liver cancer
clinical trials
Imfinzi
tremelimumab
Relay Therapeutics’ Liver Cancer Approach Paying Early Dividends
BioSpace
Sat, 10/9/21 - 11:07 pm
Relay Therapeutics
RLY-4008
intrahepatic cholangiocarcinoma
liver cancer
Merck touts a confirmatory Keytruda win for liver cancer as 'dangling' accelerated approval saga marches on
Endpoints
Mon, 09/27/21 - 10:48 am
Merck
Keytruda
clinical trials
liver cancer
FDA ends summer with fresh batch of breakthrough device designations
Medtech Dive
Fri, 09/10/21 - 11:03 am
devices
Medtech
FDA
Novocure
liver cancer
CellMax Life
Endosound
ImpediMed
Auctus Surgical
Madorra
MicroTransponder
breakthrough device
Another one bites the dust: Bristol Myers Squibb pulls 'dangling' accelerated approval for Opdivo in liver cancer
Endpoints
Mon, 07/26/21 - 09:45 am
Bristol Myers Squibb
Opdivo
FDA
liver cancer
In surprising flop, Exelixis' Cabometyx combo with Roche's Tecentriq fails to extend life in liver cancer
Fierce Pharma
Mon, 06/28/21 - 10:50 am
Exelixis
Cabometyx
liver cancer
Bayer
Nexavar
Celsion craters 65% on dim hopes for ThermoDox in liver cancer
Seeking Alpha
Mon, 07/13/20 - 12:07 pm
Celsion
liver cancer
ThermoDox
clinical trials
Roche nabs frontline OK for Avastin/Tecentriq in common liver cancer, besting an old Bayer drug
Endpoints
Mon, 06/1/20 - 10:24 am
Roche
Avastin
Tecentriq
metastatic hepatocellular carcinoma
liver cancer
FDA
ASCO: Merck, Eisai pad case for liver cancer nod with Keytruda-Lenvima combo data
Fierce Pharma
Mon, 06/1/20 - 12:00 am
Merck
Eisai
liver cancer
ASCO 2020
Keytrua
Lenvima
clinical trials
ASCO: Has AstraZeneca finally found a place for long-plagued I-O candidate tremelimumab?
Fierce Pharma
Sun, 05/31/20 - 11:58 pm
AstraZeneca
ASCO 2020
clinical trials
tremelimumab
liver cancer
Imfinzi
Bristol Myers Squibb snags new liver cancer nod for Opdivo-Yervoy combo
Fierce Pharma
Wed, 03/11/20 - 12:58 pm
Bristol-Myers Squibb
Opdivo
Yervoy
FDA
liver cancer
hepatocellular carcinoma
Roche shows Tecentriq/Avastin combo helps liver cancer patients live longer
Endpoints
Mon, 11/25/19 - 09:47 am
Roche
Tecentriq
Avastin
liver cancer
China
Bayer
Nexavar
clinical trials
Breakthrough status and promise of a speedy review arrives for Opdivo/Yervoy combination as Bristol-Myers bites at Bayer
Endpoints
Mon, 11/11/19 - 11:06 am
Bristol-Myers Squibb
Opdivo
liver cancer
Yervoy
FDA

Pages